Abbott’s Absorb is “holy grail” in coronary stents but…
Abbott's Absorb is a long-awaited, much-hyped technology to battle coronary artery disease, but its immediate success is not guaranteed.
Abbott's Absorb is a long-awaited, much-hyped technology to battle coronary artery disease, but its immediate success is not guaranteed.
FDA approves Absorb, first fully bioresorbable polymer stent, which will heat up competition with Boston Scientific's partially absorbable version.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
In the wake of the latest medical device merger and acquisition deal, and the belief that the consolidation trend will continue, here are a few thoughts on some deals I'd like to see this year.
Also, Soon-Shiong pulls in huge 2015 paycheck, Anthem remains bullish on Obamacare and Microsoft wants to store massive amounts of data on long-lasting DNA strands.
We more and more frequently hear news about the danger of concussions for athletes, football players in particular. But many average people suffer from concussions, whether from things like falls or car accidents - and they are frequently misdiagnosed.
An alternative way of testing glucose levels without finger pricking is a great solution for young kids and teens.
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
Abbott is taking the new year by storm with two acquisitions in two days. We'll see what company will be snatched up next.
Abbott is looking to vastly expand its point-of-care diagnotics options by acquiring Alere.
Google and DexCom are building a better glucose sensor; this will impact the Type 2 diabetes market and help usher in a new era of artificial pancreases.
Digital health incubator Rock Health is investing in eight new startups and teaming up with three new corporate entities – Blue Shield of California, Deloitte and global healthcare firm Abbott. The new startups being incubated span the healthcare spectrum, from HIPAA compliance to life sciences and biotech. Among them: — Accountable, an online platform that seeks […]
Abbott (ABT) announced the medical device company will voluntarily recall 20 lots of FreeStyle and FreeStyle Lite Blood Glucose Test Strips in the U.S. The company said in a statement the test strips may give low glucose readings when used with the FreeStyle Blood Glucose Meter, the FreeStyle Flash Blood Glucose Meter and the OmniPod Insulin Management […]
Amaranth Medical, a medical device company with roots in California and Singapore, has raised $20 million for a series B round. The money will support continued development of the company’s bioresorbable scaffold (a dissolving stent) technology and the CE Mark approval process. General Manager and Chief Technical Officer Kamal Ramzipoor compared the stent to a cast. […]
In this week’s healthcare design reading roundup, there’s innovation in medical device design, a hard look at the actual materials that make wearable tech wearable and a thoughtful discussion of how healing art should operate in labor and delivery. 1. Abbott is designing a stent that dissolves inside the body. 2. The five materials making […]
Current medical news from today, including Emergent BioSciences rebounds after Abbott pulls the plug on cancer drug partnership, searching for a cure for the hangover, and Avastin stabilizes ovarian cancer tumors in studies.
A GlaxoSmithKline (NYSE:GSK) cancer drug program will be developed with a new companion diagnostic from Abbott (NYSE:ABT) as GSK moves to broaden its reach in personalized medicine. Abbott recently announced it would split into two companies, one focused on drugs and another focused on medical devices and diagnostics. Under the pact with GSK, Abbott’s […]